Dr. Brandman Appointed as Medical Director for the Center for Liver Disease and Transplantation

Dr. Danielle Brandman

Danielle Brandman, M.D., M.A.S., has been appointed as the Medical Director for liver transplantation at Weill Cornell’s Center for Liver Disease and Transplantation (CLDT). The Center is run by Weill Cornell Medicine in partnership with NewYork-Presbyterian.

Dr. Brandman was recruited to Weill Cornell from the University of California-San Francisco (UCSF) by Dr. Robert Brown to serve in this role following his promotion to Chief of Gastroenterology and Hepatology in the Weill Department of Medicine. As Medical Director liver transplantation, Dr. Brandman aims to expand the existing care models for liver transplant patients with alcohol related liver disease and nonalcoholic fatty liver disease (NAFLD), as well as to improve outreach efforts to better connect patients with advanced liver disease within the transplant program.

Dr. Brandman received her B.A. in Biology and Psychology (with distinction) from Boston University, and graduated from Rutgers (formerly UMDNJ - New Jersey Medical School in Newark, New Jersey). She completed all of her postgraduate medical training at UCSF, including internal medicine in 2008, a gastroenterology fellowship in 2011, and transplant hepatology in 2012. During her gastroenterology fellowship, she completed a Master’s of Advanced Studies in Clinical Research in 2011. She joined the gastroenterology faculty at UCSF in 2012, where she held several leadership roles in medical education and clinical care. She served as Program Director for the ACGME-certified Transplant Hepatology Fellowship and was the director of resident and fellow rotations in liver transplantation and hepatology. Her teaching and mentoring skills were recognized with an Excellence in Teaching Award from the UCSF Haile T. Debas Academy of Medical Educators and the Mentor of the Year Award by the UCSF Clinical and Translational Science Institute Resident Research Program. She has served as a mentor for the American Association for the Study of Liver Disease (AASLD) for several Emerging Liver Scholars.

Dr. Brandman’s major area of clinical and research interest has been NAFLD (nonalcoholic fatty liver disease), and was the director of the Fatty Liver Clinic while at UCSF. Her work has focused on noninvasive assessment of NAFLD severity, with a goal of accurately identifying patients with NAFLD who are at risk for severe disease. with work published from collaborations within the NIH-funded NASH Clinical Research Network, as well as industry-funded work in collaboration with primary care providers. She was the site Principal Investigator for the multicenter study, NAIL-NASH, which evaluates outcomes in liver transplant recipients with NASH. Together with advanced practice providers (APPs), she developed Behavioral Resources and Intervention through Digital Group Education (BRIDGE), which is an APP-led telehealth program that educates patients about their diagnosis of NAFLD and provides them with the skills needed to engage in behavior change to improve liver health.